The objective of the present study was to evaluate the cellular effects of the oncolytic HSV-1 based vector, G207, on the tumor microenvironment. We established progressively growing intracerebral xenografts in athymic nude rats generated from three different human GBM surgical specimens. The lesions were identified by MRI and subsequently injected with a concentrated vector stock. The animals were killed 10 or 30 days after G207 injection and the tumors were quantitatively evaluated for virus-induced changes in proliferation, apoptosis and vascularity. Moreover, we assessed vector spread as well as the infiltration pattern of CD68-positive inflammatory cells. In all G207-injected lesions, immunostaining identified widespread regions of viral infection and replication (plaques). Proliferation indices were significantly lower, whereas apoptotic counts were significantly elevated in plaques as compared with that in non-infected areas of the same lesions, as well as in corresponding control xenografts. Furthermore, there was a significant decline in the number of blood vessels in the plaques and the vascular area fractions were reduced. CD68-positive inflammatory cells accumulated in the plaques. The present study highlights the favorable cellular responses to G207 treatment seen from a clinical viewpoint, such as reduced tumor cell proliferation, more frequent events of tumor cell death and a strongly attenuated tumor vascular compartment. However, our results suggest that transduction of a significant volume of tumor tissue is essential, as these beneficial changes were only observed in areas of active viral replication, leaving non-transduced tumor tissues unaffected.
Introduction
The oncolytic HSV-1-based vector, G207, was originally designed to treat malignant brain tumors. 1 Since HSV-1 is neurotropic, G207 was genetically attenuated to restrict its replication in cells of the normal central nervous system, and at the same time to maintain it in proliferating malignant cells. HSV-1 replication inevitably leads to demise of the infected host cell through virus-mediated lysis. To spare normal CNS tissue, G207 was attenuated by deleting both copies of the g34.5 neurovirulence gene and by disrupting the ICP6 coding region in the vector genome by insertion of the bacterial lacZ sequence.
1 ICP6 codes for ribonucleotide reductase, an enzyme required for viral DNA synthesis in quiescent cells, which is dispensable in proliferating cells. 2, 3 Safetymodified G207 proved to sustain a non-neurotoxic profile after intracerebral administration in rodent and simian models. 4, 5 For malignant glioma, G207 has been evaluated in a phase-I clinical dose-escalation trial, 6 and recently phase-Ib trial results were published. 7 Stereotactic intratumoral inoculation of 3 Â 10 9 plaque-forming units of G207 was not associated with serious adverse events or toxicity; however, significant decreases of tumor mass were only detected in a subset of patients. 6 The recent phase-Ib trial confirmed that the maximum achievable dose, 1.15 Â 10 9 , is safe when delivered before resection as well as after resection to the tumor-infiltrated normal brain tissue. 7 Therefore, subsequent developments of HSV-1-based glioma therapy have focused on ways to enhance antitumor efficacy. 8 Two main strategies have been followed: modifying the vectors by deleting the immunoattenuating genes coded for by the virus, to allow enhanced immunorecognition of vector-infected cells, 9 or, by inserting immunostimulatory or therapeutic transgenes, [10] [11] [12] [13] as well as by combining the vectors with other clinical treatment forms such as chemotherapy 14 or irradiation. 15 In neuro-oncology, the validity of experimental data obtained from preclinical evaluation of potential clinical therapies has been compromised by the widespread use of tumor-cell-line-based animal models. Typically, glioma cell lines that are maintained as monolayers start to express mesenchymal markers, 16, 17 and xenografts established from such lines grow as circumscribed lesions that do not reflect the infiltrative behavior of human gliomas. 18, 19 Using a different approach, glioblastoma (GBM) biopsy material obtained at surgery may be cultured in the form of multicellular spheroids, where the essential phenotypic characteristics of the tumor tissue are retained. 20 Direct transplantation of such 'organotypic' spheroids into rodent brains forms lesions that eventually recapitulate all the histopathological hallmarks of GBM in situ, such as extensive single-cell infiltration, angiogenesis the occurrence of necroses with palisading tumor cells, endothelial proliferations and dilated, thrombotic vessels. 18, 21 We have recently used this model to evaluate gene transfer to human GBM cells 22, 23 as well as to study the biological aspects of tumor cell invasion. 24 Since the described model reflects the key features of human glioma progression, we chose to assess the effect of G207 on a set of xenograft phenotypes that follow these biological features. The objective of this study was to quantify the effects of this vector, which is in clinical therapy, on biological markers with prognostic value within the tumor microenvironment. In particular, we wanted to quantify the changes in tumor cell proliferation, apoptotic figures and microvascular parameters within areas of viral replication (foci or plaques) and compare these figures with non-infected fields in the same G207-injected tumors, as well as non-injected control tumors. Moreover, we wanted to assess cellular responses to active herpes viral replication by identifying the invasion pattern of CD68-positive inflammatory cells around the plaques.
Convection-enhanced delivery of a concentrated G207 stock preparation into intracerebral xenografts derived from three different patient biopsies resulted in several foci of active vector replication, as demonstrated by immunostaining for late viral gene products. Tumor cells that were localized within plaques of viral replication showed reduced proliferation rates. Significantly more apoptotic figures were seen in plaques in all lesions treated by G207. Blood vessel counts and vessel area fractions were significantly reduced in plaques. There was enhanced concentration of inflammatory cells within and around the foci, consistent with release of intracellular content from lysed tumor cells and activation of CD68-positive microglia and tissue macrophages.
To our knowledge, this is the first time these biological markers were directly correlated to areas of replication as compared with non-infected neighboring and distant tissue areas in the same lesion in a relevant preclinical model.
Results

Tumor engraftment
The tumor take of human GBM spheroids in the current animal model is close to 100% as published previously. 18, 21 All the animals investigated by MRI scans showed presence of lesions and tumors were confirmed in all of the animals included in this study after post-mortem analysis. Typically, vascularized lesions were contrastenhancing and could be easily discerned at an early stage on T2-weighted MRI (Figure 1 ). Lesions of GBMI appeared on MRI scans 78 days post implantation, whereas lesions of GBMII appeared 60 days post implantation and GBMIII appeared 21 days post implantation. Median survival for animals implanted with the three lesion types when allowed to proceed to killing were as follows: GBMI, 134 days; GBMII, 76.4 days and GBMIII, 60.5 days. In this study, the animals were injected with vectors within 1 week after confirmation by MRI and sacrificed at 10 or 30 days post vector injection.
Histopathological features of the lesions
GBM biopsy spheroids derived from three different patients were implanted into nude rats. The resulting xenografts displayed characteristic histological features of human GBM (presented in Figure 2 , Supplementary Figure S1 and Table 1 ). When implanting the same patient-derived spheroids, the resulting lesions displayed consistent histology as corroborated by hematoxylin and eosin staining on post-mortem analysis of the animals as described previously.
18,21
Histological changes associated with herpes viral infection
We analyzed the lesions that were injected with G207 for the extent of vector spread and histological changes. Intratumoral delivery of G207 resulted in several large foci (or plaques) of viral replication distributed throughout the lesions as observed after immunostaining for HSV-1-infected cells (Figures 2a and c) . The antibody used labels structural viral proteins, specifically identifying all the major capsid glycoproteins, as well as a core protein expressed in cells where active herpes viral replication takes place. Plaques were also evident on hematoxylin and eosin-stained sections as areas of cytolytic clearing, which may be seen after numerous events of vacuolar cytoplasmic degenerations (Figures 2b  and d) . The cellular histology of saline-injected lesions GBMI and GBMII are shown in high power in Figures 2e and f, respectively. Whereas GBMI showed high degree of cellular atypia, GBMII lesions contained less polymorphic nuclei. Upon G207 delivery, classical morphological changes associated with herpes viral infection, such as nuclear molding, vacuolar cytoplasmic degeneration, eosinophilic intranuclear inclusions and chromatin margination, were evident in both lesions (Figures  2g-i) . Immunostaining for HSV-1 revealed cells with the above mentioned histological changes as well as infected cells at an earlier stage of the viral life cycle where the morphologic changes were not yet evident (Figures 2j  and k) . The G207-associated histological changes did not differ between the xenografts derived from different patients (Figures 2g-k) and data published previously. 25 
Proliferation rates in G207-infected plaques
We immunostained xenograft sections for Ki-67 to evaluate proliferation indices. For all xenografts GBMI, GBMII and GBMIII, decreases in the number of proliferating cells were clearly evident in plaques (Figures 3a-c) as compared with non-infected areas in vector-injected tumors (Figures 3d-f) . Control xenografts not treated with G207 appeared to have higher proliferation rates in all cases (images not shown). We quantified changes in proliferation for all xenograft types comparing viral plaques with areas not affected by G207 as well as control tumors that were not injected with the vector. In xenograft GBMI (Figure 3g ), the median number of Ki-67-positive nuclei in distant non-infected regions was The proliferative rate was significantly reduced in plaques as compared with distant non-infected fields as well as in non-infected fields bordering the plaques compared to fields distant from plaques (post hoc multiple comparisons, P ¼ 0.001 and P ¼ 0.002). No significant difference in the proliferation rates were found between plaques and non-infected fields bordering the plaques (post hoc multiple comparisons, P ¼ 1.00) for this xenograft. In the control animal, median number of Ki-67-positve nuclei was 27.81% (range 21.94-33.17, mean 28.17, s.d. 4.30). This was not significantly different from the proliferation index found in non-infected fields in G207-injected tumors (P ¼ 0.527), indicating that proliferation index is not affected in regions where there is no detectable viral replication in these injected lesions.
In the GBMII xenografts (Figure 3h ), the median number of Ki-67-positive nuclei in non-infected regions was 12 Figure 1 Vector delivery and analysis of G207-injected xenogafts. Tumor take was verified by MRI. G207 stock was injected into the center of the growing tumors (a). Ten (short-term effects study) or 30 days (later-effects study) after vector injection, the brains were processed for HSV-1 immunohistochemistry, which identified viral plaques (foci of replication, brown staining). Other parameters were quantified after immunostaining for the respective markers and for quantifying immunopositive cells in fields defined as plaque (b, right, brown staining), plaque border (microscopic field immediately adjacent to plaques; b red box) or non-infected areas (b, lower left) in injected lesions. The selected parameters, such as proliferation, apoptosis and measures of vascularity, were compared between fields in vector-injected xenografts with those found in non-injected-or saline-injected control animals. MRI, magnetic resonance imaging. d) . Appearance of the GBMI xenograft exhibiting multiform histology (e). GBMII xenograft with a more uniform appearance and high cellularity (f). Both xenograft types show classical signs of HSV-1 infection and replication, after treatment with G207 vector. Nuclear molding (arrowheads), vacuolar cytoplasmic degeneration (asterisks) and eosinophilic intranuclear inclusions and chromatin margination (arrow) are evident (g). HSV-1 antigen-specific staining identified G207-infected cells, both those where the above mentioned changes were seen as well as infected cells where the histological changes were less evident. (a, b, e, g, j) GBMI; (c, d, f, h, i, k) GBMII. Scale bars: (a-d) 1 mm; (e-k) 20 mm. PFU, plaque-forming units.
Oncolytic herpes viral therapy in GBM xenografts PC Huszthy et al For GBMIII lesions in the later-effects study (Figure 3i ), the median proliferative index in plaques was 16 10 .73). The noninfected regions in vector-treated animals had significantly higher proliferation rate than the levels found in saline-injected control animals (Po0.001), indicating a possible compensatory response to the reduced proliferation in plaques. When comparing all fields between G207-injected rats with saline controls, we only obtained a trend toward reduced proliferation (P ¼ 0.099).
Double immunostaining, which identified dividing cells and vector-infected cells, illustrates how plaques containing G207-infected cells (red) show absence of the Ki-67 proliferation marker (Figure 3j ), whereas plaque borders show increased proliferation as compared with plaques ( Figure 3k , left and right side of the image, respectively).
Apoptotic rates in G207-infected areas
We immunostained sections from all xenograft types for cleaved caspase-3 to evaluate the number of apoptotic cells in GBM tissue affected by G207. For GBMI, GBMII and GBMIII xenografts, increases in the number of apoptotic cells were evident in plaques (Figures 4a-c) as compared with that in the non-affected areas (Figures 4d-f ). Further, we quantified the changes in the number of apoptotic cells in plaques versus nonaffected fields.
In GBMI lesions (Figure 4g ), control animals had a median of three apoptotic counts per Â 400 field (range 2-4, mean 2.70, s.d. 0.675). In G207-injected GBMI lesions, the plaques had a median of seven counts per Â 400 field (range 7-12, mean 8.25, s.d. 2.5). The difference was significant (Mann-Whitney U-test, P ¼ 0.002).
In control animals harboring xenograft GBMII ( Figure  4h ), the median of was three counts per Â 400 field (range 2-6, mean 3.1, s.d. 1.29), whereas in the plaques it was 49.5 counts per Â 400 field (range 38-89, mean 57.5, s.d. 18.67) counts. The observed increase in apoptotic figures was highly significant (post hoc multiple comparisons, Po0.001). For this xenograft, we have also evaluated the number of apoptotic cells outside the foci of viral replication, in the same infected lesion. Here, we obtained a median of 11.0 apoptotic counts per Â 400 field (range 7-21, mean 13.0, s.d. 4.40) . The increase in the number of apoptotic counts in plaques as compared with non-infected regions in G207-injected GBMII lesions was highly significant (post hoc multiple comparisons, Po0.001). The difference between the non-infected regions in the G207-injected tumors and the salineinjected control tumors was not significant (post hoc multiple comparisons, P ¼ 0.66).
In the later-effects study (GBMIII; Figure 4i ), a median of four counts was seen in plaques (range 0-110, mean 12.18, s.d. 23.23), whereas in the non-infected regions the median was one count (range 0-54, mean 6.47, s.d. 15.46). Although there were large variations between the counts within both groups, the increase in apoptotic counts in plaques as compared with control tumor regions was significant (P ¼ 0.005). In the vector treatment group, one rat experienced intratumoral bleeding, characterized by widespread, massive accumulation of erythrocytes in the tissue. In this animal, the apoptotic counts were dramatically elevated as compared with that in the other rats; median 53.5 counts (range 3-110, mean 57.8, s.d. 28.81) versus median 2 counts for the others (range 0-14, mean 3.26, s.d. 3.73). Thus, intratumoral bleeding strongly upregulated tumor-cell apoptosis in our setting (Po0.001). This animal was included in our evaluation of apoptotic counts.
Microvessel density in G207-infected areas
We immunostained sections from all the treatment group animals with GBMIII xenografts (late effects study) for von Willebrand factor, a large glycoprotein that is expressed in the blood plasma and on platelets, as well as on endothelial cells lining vessel lumens and on the sub-endothelial matrix of vessel walls. 26 The antibody is routinely used to envision vascular elements in tissues. The absence of vascular elements were seen within plaques, and the number of vessels were clearly reduced in plaque-containing fields ( Figure 5a ) as compared with that in non-infected fields ( Figure 5b ) and saline-injected control lesions (Figure 5c ).
Furthermore, we quantified these changes ( Figure 5d ). Blood vessel counts were collected from von Willebrand factor-stained sections taken from the two group of animals treated either with 6.8 Â 10 6 PFU G207 (45 fields) or saline (48 fields). In saline-treated tumors, the median blood vessel density was 19.5 vessels per Â 400 field (range 9-42, mean 20.06, s.d. 6.83). In fields representing actively replicating (HSV-immunopositive) plaques, the median number of vessels was 11 counts per field (range 7-25, mean 12.48, s.d. 5.59). In vector-injected tumors, in the non-infected fields, the median blood vessel counts were 24.5 vessels per field (range 12-46, mean 24.96, s.d. 8.04). Using mixed linear model analysis, we found significant reduction in microvessel numbers in infected plaques as compared with that in non-infected tumor areas with control areas from salineinjected animals. The difference in vessel numbers between non-infected fields in G207-injected animals and the saline-injected animals was not significant (P ¼ 0.09). as compared with that in non-infected xenograft areas as well as in the control tumors of the same xenograft type (d-f). Scale bars: (a-k) 100 mm. Quantification of proliferation rates in control lesions, non-infected areas, plaques and plaque borders for GBMI (g) and GBMII (h). The figures show significantly reduced proliferation rates in the plaques. For GBMIII (later effects study) the figure similarly shows a reduced proliferation rate in plaques compared to both control xenografts as well as non-infected regions (i). Xenograft sections that were doublestained against herpes simplex vector antigens (red) and Ki-67 antigen (brown) illustrating the absence of proliferating cells in the plaques (j). An image (k) that encompasses both plaque (right side) and surrounding non-infected areas (left side) highlights this difference. CTRL, saline-injected controls; NI, non-infected fields in vector-injected tumors; plaque, plaques of viral replication in vector-injected tumors and Pl. border, non-infected fields at the immediate borders of replicative plaques. Proliferation index was defined as the percentage of cells staining positively for Ki-67 per Â 400 field. GBM, glioblastoma.
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Vessel area fractions in G207-infected areas
Vessel area fractions were quantified from the same von Willebrand factor-stained sections as those used for vessel density evaluation (Figure 5e ). In control tumors, the median vessel area fraction was 2.20% per field (range 1. , when comparing non-infected tumor areas between the two groups. This difference in vessel areas between non-infected fields in G207-injected animals and in micoscopic fields in saline-injected animals was not significant (P ¼ 0.325), again suggesting that G207 had no noteworthy effects on the area occupied by blood vessels outside regions of active viral replication.
Distribution of macrophages and microglia in the xenografts
To evaluate the spatial distribution of tissue macrophages and microglia in the xenografts infected by G207, we immunostained paraffin-embedded sections with an antibody raised against rodent-specific CD68. In salineinjected GBMII lesions, CD68-positive cells were found localized in some tumor areas close to the tumor-brain border and scattered around some invasive tumor cells (Figure 6a ). CD68-positive cells were also found under the meningeal lining as well as between choroid plexus ependymal cells in areas where the ventricles were overgrown with tumor (data not shown). The central tumor mass was devoid of CD68-immunopositive cells (Figure 6d ). In G207-injected GBMII lesions, CD68-expressing cells were found in a pattern similar as controls in peripheral tumor and around invasive cells (Figure 6b ). In addition, strong accumulation of CD68-positive cells was found 
Infection of infiltrative glioma cells by G207
To evaluate if G207 exhibits tumor specificity in the current model, we performed double labeling against human-specific vimentin and HSV-1 and evaluated xenografts as well as invasive cells within the brain. The vimentin-specific antibody uniformly labels human tumor cells in the GBM spheroid model. 22, 25 Lowmagnification images confirmed single-tumor-cell infiltration into the corpus callosum in GBMI lesions (Figure 7a ). Central areas in this xenograft stained for vimentin, whereas anti-HSV-1 antibody labeled G207-infected cells (Figure 7b ). G207-transduced cells found in host brain areas were all positive for vimentin, whereas non-labeled resident cells were not infected (Figure 7c) . Figure 7d is a higher power view of 7B showing colocalization of HSV-1 and tumor-cell-specific signal in polymorphic GBM cells.
Discussion
Transduction of human GBM biopsy tissue engrafted in nude rats Upon delivery of 10 ml G207 vector using microprocessor-controlled slow infusion, we obtained transduction of extensive tumor areas in xenografts obtained from different GBM patients (Figure 2) . Previously, we have determined that 3.4 Â 10 6 PFU of concentrated G207 vector preparation transduces 7 mm 3 of GBM tissue. 25 Interestingly, we obtained similar transduction volumes using pseudotyped lentiviral vectors (LV) in a study where GBM xenografts were initiated from the same patient biopsy. 27 Lymphocytic choriomeningitis viruspseudotyped LV transduced 7.05±3.51 mm 3 volume of tumor tissue, whereas vesicular stomatitis virus-pseudotyped LV transduced 4.05±2.04 mm 3 tissue. When applied at the same total volume of concentrated stock as used with G207, both lentiviral vectors mediated tumor regression through thymidin-kinase-assisted suicide gene therapy. Although the tissue volumes transduced by LCMV-pseudotyped LV is very similar to that obtained after delivery of G207, the tk-encoding vectors have an inherent bystander activity, enabling them to kill tumor cells that have not been infected. 28 The current data suggest that G207 does not possess such a bystander activity, since tumor regions even at the immediate vicinity of transduced areas were left unaffected. The comparison indicates that application of therapeutic transgenes, which provide a bystander effect might significantly improve the efficacy of oncolytic vectors.
Effects on tumor-cell proliferative index
The Ki-67 nuclear protein is expressed in all active phases of the cell cycle and the Ki-67 labeling index is routinely used to describe the proliferative rate of tissues. 29 Moreover, Ki-67 expression correlates with protein synthesis and metabolism in tumors. 30, 31 The prognostic value of the Ki-67 index has been established in the majority of tumor types, including brain tumors, 32, 33 where a higher labeling index is associated with a shorter survival. 29 We have shown that in all our patient GBM xenografts that the number of Ki-67-positive cells was significantly reduced in the areas with active replication both after 10 and 30 days of vector administration. The observed reduction in the Ki-67 index in plaques is due to the fact Figure 5 Blood vessel density and microvascular areas are reduced in G207-infected tumor regions. GBMIII xenografts were injected with 6.8 Â 10
6 PFU G207 and killed 30 days post injection. The brains were immunostained for von Willebrand factor to visualize vascular elements. Less von Willebrand factor-positive vascular elements were found in fields containing plaques (a) than in fields with non-infected regions (b) as well as fields taken from control tumors (c). It is evident that in fields containing plaques, the blood vessels are located between the viral replication foci rather than inside them. Note also the more dilated blood vessels in control tumors. Quantitative evaluation of blood vessel counts (d) and vascular area fractions (e) both show reduced vascularity in viral plaques. Scale bars: (a-c) 100 mm. CTRL, salineinjected controls; NI, non-infected fields in vector-injected tumors and plaque, plaques of viral replication in vector-injected tumors. Microvessel density was defined as the number of von Willebrand factor-positive vascular structures per Â 400 field, whereas vascular fraction areas were defined as the percentage of the total microscopic field occupied by blood vessels. GBM, glioblastoma; PFU, plaqueforming units.
Oncolytic herpes viral therapy in GBM xenografts PC Huszthy et al that HSV-infected cells are precluded from entering into or completing cell division, 34 an effect induced by the viral ICP0, ICP4 and ICP27 proteins. 35, 36 In control animals, we found Ki-67 labeling indices between 15 and 32%, which are in line with the values previously observed in the biopsy xenograft model, 18 and are somewhat higher than the values reported for human GBM in situ. [37] [38] [39] In xenograft GBMII, we obtained a remarkable 84% reduction of proliferating cells in plaques after G207 treatment, with 2.5 percent Ki-67 positivity, a figure that resembles grade-II astrocytomas in humans. 33 In the two other xenograft lesions, we obtained 43 and 50% reduction rates, to give a 16% labeling index in both lesions. Notably, non-infected regions of vector-injected xenografts in the long-term effects study had significantly higher proliferation rates than saline-injected controls, suggesting that non-infected tumor cells may compensate the vector's antitumor effect by accelerating their doubling times.
However, in the lesions where the immediate plaque borders were examined 10 days after administration, we did not see any significant changes in this regard. Even though G207's antiproliferative effects were clear in plaques, when comparing all fields between vector and control groups, the differences were not significant. These results are typical for molecular therapeutic approaches of today, indicating that insufficient transduction, rather than the biological properties of the vector, limit antitumor efficacy.
Effects on tumor-cell apoptosis
Apoptosis is the host cellular response, which serves to limit the proliferation and spread of viral particles. 40 Herpesviruses induce, and subsequently interrupt, apoptosis, enabling them to complete their life cycle and spread through the tissue. 41 We have chosen to quantify the events of programmed cell death by immunostaining for cleaved caspase-3, an executor Oncolytic herpes viral therapy in GBM xenografts PC Huszthy et al caspase activated by both intrinsic and extrinsic apoptotic pathways. 42 In HSV-1, antiapoptotic activity has been assigned to immediate-early proteins ICP4, ICP27, U S 3, ICP22, glycoprotein-D and J, and others, 41 whereas ICP0 was found to be necessary (and sufficient) to induce the initial apoptosis induction event associated with HSV-1 infection. 43, 44 G207 is not modified in the coding sequences that relate to apoptosis, and is, therefore, expected to behave as wild-type HSV-1 in this regard. Our data show significant increase in apoptotic figures in the regions of active viral replication in all three xenografts. GBMIII showed a large variation within the treatment groups; variation was also present in the control group. This variation was also present in the data describing proliferation as well as vascular parameters. It is unlikely that these cells are actually infected, since G207 interrupts apoptosis in cells it enters. More probably, caspase-positive cells are neighboring cells that sense tissue damage, possibly after the release of cellular proteins from lysed cells, and respond by undergoing programmed cell death.
In terms of clinical applicability, induction of apoptosis in vector-infected cells is a disadvantage, which limits vector spread and oncolytic killing, whereas any apoptosis occurring in neighboring, non-infected cells is a benefit, resulting in an additional 'bystander effect'. The observed more than 1500-fold increase in apoptotic figures in the GBMII xenograft may well be a significant figure from a clinical viewpoint. The relative sensitivity of this patient tumor xenograft may be due to its differential expression of proteins that are involved in regulating the apoptotic response to HSV-1. We have previously shown that apoptosis may occur in certain susceptible normal brain cells, and that some host cells may support productive infection by the attenuated G207 mutant. 25 Host cell infection is an undesired effect, and today care is taken in the clinical setting to avoid possible infection of the herpes-susceptible ventricular ependyma by G207.
Effects on the tumor vascular compartment
For analysis of G207 on vascular parameters, we chose GBMIII, which histologically recapitulates all the characteristics of GBM in situ, displaying necrotic areas and extensive vascularization (Table 1 and Supplementary  Figure 1) . To evaluate the effects of the oncolytic herpes viral vector on tumor blood vessels, we killed the animals 30 days after vector injection to allow the vector to mediate its possible angiostatic effects for a prolonged period of time. In foci of G207 replication, mean vessel counts and vascular area fractions were found to be significantly reduced when comparing both with values in the non-infected fields in the same tumors as well as with those in the saline-injected controls. The mean vessel counts were about 26% percent higher in noninfected areas (which did not stain for HSV-specific antigens) as compared with that in saline-injected controls, a difference that did not reach the applied level of significance. It should be mentioned that vessel density counts and area fractions vary substantially in GBM, even within the same lesion, without any Oncolytic herpes viral therapy in GBM xenografts PC Huszthy et al therapeutic intervention. Angiogenesis is induced around necrotic regions through upregulation of the main angiogenesis inducer vascular endothelial growth factor. Necrosis in GBMs results from insufficient supply of oxygen and nutrients required by rapidly expanding glioma cells. However, the necrotic areas observed in plaques after G207 application are a result of viral replication and lysis rather than an insufficient oxygen/ nutrient supply, and, therefore, the relation to angiogenesis induction here is not evident. The vessel area fractions in non-infected fields in vector-injected animals were lower than those in the saline-injected controls, suggesting that even if there was a slight upregulation of vessel numbers here, these microvessels have less dilated lumens and lengths.
Previous reports have studied the effects of G207 or other oncolytic herpes vectors on the tumor vasculature. 11, 45, 46 In one study, mice bearing rhabdomyosarcoma xenografts were injected intratumorally with G207. 45 Eight days post injection, endothelial structures were found to be absent in the vector-injected lesions, and the authors detected enveloped viral particles in endothelialcell cytoplasms. 45 Other studies showed that G207 enhanced mean blood vessel densities, a finding explained by reduction of the intratumoral levels of the angiogenesis inhibitors thrombospondin-1 and 2.
11
Our results seem to be partially in line with those in the former publication. In microscopic fields containing foci of replication, the vessels were generally smaller, less dilated and elongated, and were often found at the borders of the plaques rather than within central areas of clearing. It is unclear if the reduction in vascularity was due to direct infection and lysis of the endothelial lining, or if it was a secondary effect possibly connected to a decreased number of tumor cells in plaques, and, thereby, a reduced oxygen demand in infected areas. This may lead to vessel regression through failure to maintain the endothelium by proangiogenic factors such as vascular endothelial growth factor, which is required for endothelial-cell survival. 47 In one xenograft, we observed widespread dispersion of erythrocytes throughout the tumor mass after G207 delivery, suggesting possible infection and rupture of the tumor endothelial wall. However, we failed to localize HSV-specific antigens to endothelial cells by immunostaining, which would have proved this point. Our observation that noninfected areas in G207-treated tumors had slightly elevated blood vessel counts as compared with that in the saline-injected control xenografts, resembles data published previously advocating that G207 (and the related hrR3) is proangiogenic. 11, 46 Therefore, it seems that G207 directly or indirectly reduces vascularity in areas it infects; however, adjacent tumor areas may try to counteract this effect by inducing angiogenesis. Of note, none of these studies investigated the extent of viral transduction in the tumors, nor have comparisons been made in vessel counts between infected (HSV-immunopositive) and non-infected microscopic fields.
Importantly, our results indicate that in tumor regions successfully transduced by G207, both the mean vessel densities and area fractions occupied by blood vessels are significantly reduced. This is an immediate advantage for GBM patients, since insufficiently vascularized tumor regions will die by necrosis. On the other hand, widespread infection and cytolysis of the endothelial lining and subsequent excessive hemorrhages may result in cerebral infarction and demise of the patient. For the angiostatic effects of G207 to be clinically meaningful, it would be of importance to achieve as geographically widespread a transduction as possible by administering the vector using convection-enhanced delivery or employing multiple injections to the tumor resection cavity.
Infiltration by CD68-positive cells in areas of active viral replication
We have found that CD68-positive microglia or brainresident activated macrophages accumulate in the invasive zone of intracerebral gliomas, a finding also reported by others. 48 In contrast, accumulation of CD68-positive cells within the tumor bed was only observed around viral plaques. Whether the inflammatory cells were present due to natural killer cell-induced interferon-g or were they recruited by other means to phagocytose virus-lysed cells is not clear. The ED1 antibody clone used in our study recognizes the rat homolog of CD68. It labels monocytes, activated microglia and tissue macrophages. 49, 50 A recent study has found that in Fischer rats, the numbers of natural killer cells as well as CD68-immunopositive cells and the levels of interferon-g increased rapidly after intratumoral delivery of an oncolytic herpes vector. 51 The inflammatory response was associated with decrease of vector-infected tumor volumes, underlining that the activity of activated monocytes and phagocytic cells limits transduction efficiency and, thereby, antitumor efficacy. In a recent clinical study, elevated levels of monocytes, macrophages and microglia were also seen in five of six patients evaluated. 7 
Infection of invasive glioma cells by G207
We confirm that G207 is tumor cell-specific when delivered intracerebrally in immunodeficient nude rats. This finding corresponds to previous data from mice and simian models. 4, 5 Although transient infection of the cerebral ventricular ependyma in rodents may occur, 5, 25 this was not seen in the current study. Ependymal infections are seen in rare cases where the vector escapes to the ventricular cavities. In the clinical setting, care is taken to avoid vector contact with the ventricular system. 7 In our data set evaluating 18 rats implanted with brain tumor xenografts, no HSV-1-specific staining was seen in normal brain tissues in any of the animals after G207 treatment.
In conclusion, we have determined the cellular effects of oncolytic viral therapy in human GBM patient tissue using progressively growing tumor xenografts in nude rats. A significant decline in tumor-cell proliferation, increases in apoptotic figures and decreased vascularization was observed in regions where G207 replication was detected, whereas non-infected regions in the treatment group remained largely unaffected. These results held true both 10 and 30 days post vector administration. This suggests that the concept of oncolytic herpes viral therapy in human GBM therapy is valid; however, to be clinically meaningful, two ways could be envisioned to improve their efficacy. Either more of the lesion needs to be transduced, which may be achieved by physical or chemical methods, such as convection-enhanced delivery or protease pre-treatment, 52 or through enhancing effi-
Oncolytic herpes viral therapy in GBM xenografts PC Huszthy et al cacy by using therapeutic genes to provide oncolytic HSV vectors with a bystander effect to target nontransduced tumor cells. It is also important that viral replication be maintained through longer periods of time to obtain therapeutic benefit. The evidence from this and other studies showing increased monocytic infiltration after G207 delivery and, thereby, possible attenuation of therapeutic effect, presents scientists with novel challenges for oncolytic HSV design and therapy.
Materials and methods
Vector production
The G207 vector was obtained from MediGene AG (Martinsried, Germany). The vector was produced and titrated as described. 1 The stock was filtrated, concentrated by size-exclusion chromatography and tested for sterility and endotoxin. The infectious titer of the stock solution was 3.4 Â 10 8 PFU ml
À1
.
Tissue culture
Tumor fragments from GBM patients were obtained at surgery. The collection of biopsy tissue was approved by the regional ethical committee. Tissue specimens were taken from viable tumor areas that corresponded to regions with contrast enhancement on preoperative magnetic resonance imaging (MRI) scans. The specimens were transferred to test tubes containing complete growth medium, Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 2% L-glutamine and four times the prescribed concentration of non-essential amino acids, penicillin and streptomycin. Spheroids were prepared as described previously. 20 Briefly, tissue samples were minced into approximately 0.5-mm fragments and placed into 80-cm 2 tissue culture flasks (Nunc, Roskilde, Denmark) base coated with 0.75% agar (Difco, Detroit, MI, USA). The spheroids were maintained in a standard tissue culture incubator with 5% CO 2 and 100% relative humidity at 37 1C. The medium was changed once a week.
Tumor growth in immunodeficient rats
Athymic nude rats (rnuÀ/rnuÀ) were implanted with biopsy spheroids generated from GBM patients. Surgery was performed as described previously. 25 Briefly, a burrhole was drilled 1 mm posterior to the bregma and 3 mm to the right of the midline suture, and 10 or 15 GBM spheroids (diameter 400 mm-600 mm) were implanted into the cerebral cortex at 2.5-mm depth using a Hamilton type 7125 syringe (Hamilton, Bonaduz, Switzerland). The handling of the animals and the surgical procedures were performed in accordance with the Norwegian Animal Act and the local ethical committee approved the protocol. Tumor growth was visualized at regular intervals using a Bruker Pharmascan 7-T MR scanner (Bruker Biopsin MRI GmbH, Ettlingen, Germany) (Figure 1a ).
Study plan
Spheroids were generated from three different human GBM surgical specimens. The xenografts generated from these (designated as GBMI, GBMII and GBMIII) displayed distinct, characteristic histological features. The tumors were scored by a neuropathologist. To evaluate the short-term effects of G207, we delivered 10 ml of G207 vector stock (3.4 Â 10 6 PFU to MRI-confirmed lesions (GBMI and GBMII)). We observed the animals for 10 days after injection before killing and tissue processing. Differences in proliferative index (Ki-67 staining), apoptotic index (cleaved capspase-3 staining) and infiltration of tissue macrophages and microglia (CD68 staining) were evaluated together with the histological characteristics of the injected lesions. To evaluate later effects of G207, we injected 20 ml of G207 (in total, 6.8 Â 10 6 PFU) into the xenografts (GBMIII) and observed the animals for 30 days before killing. For GBMIII, two study groups were established, which were injected with either vector or with sterile saline during the same operative session. We evaluated the differences in proliferative rates and apoptotic indices between the two groups. In addition, we compared the effects of G207 on tumor microvessel density and vascular area fraction figures with salineinjected controls.
Cellular parameters were quantified after immunostaining for the respective markers and for quantifying immunopositive cells in microscopic fields defined as plaque (Figure 1b , right, dark stained areas), plaque border (Figure 1b , right) or non-infected areas (areas that were not in the direct vicinity of plaques) in injected lesions. The selected parameters were compared between fields in vector-injected xenografts with those found in salineinjected control animals.
Vector infusion
When tumor take was confirmed, the animals were anaesthetized and prepared for vector injection. The skin was carefully withdrawn to reveal the location of the injection site. A 10-ml volume of G207 vector stock (3.4 Â 10 6 PFU) was drawn up in a glass syringe (model 701; Hamilton). The syringe was secured in a microprocessor-controlled infusion pump (UMP 2-1; World Precision Instruments, Stevenage, UK) connected to the stereotaxic frame. The needle tip was navigated to the injection site and inserted at the same coordinates as used for spheroid implantation (Figure 1a, right) . Vector infusion was performed in the course of 45 min. After infusion, the needle was left in place for 5 min to avoid vector reflux. The needle was slowly retracted and the skin folds were closed with polyamide surgical thread. Following surgery, rats were allowed to recover in an incubator set at 35 1C before returning them to the cages.
For the long-term effects study, two injections of 10 ml each were delivered at two different stereotactic locations within the lesion during the same operative session, for a total dose of 6.8 Â 10 6 PFU per animal.
Preparation of brain sections
The brains were removed, rinsed twice in 1 Â phosphatebuffered saline and fixed in 4% neutral-buffered formalin for 3 days. The tissues were embedded in paraffin and 6-mm-thick sections were prepared. Every fifth section was stained with hematoxylin and eosin.
Immunostaining
Paraffin-embedded sections were placed in xylene for 2 Â 3 min, absolute ethanol for 2 Â 3 min, 96% ethanol for 2 Â 2 min and finally in distilled water for 30 s. Epitope retrieval and incubation conditions are indicated in Supplementary 
Light microscopy
For images with magnifications of Â 40 to Â 400, a Nikon Eclipse E600 light microscope was used with an attached Nikon DXM1200 digital camera and Nikon Plan Fluor objectives ( Â 4, Â 10, Â 20 and Â 40; Nikon Instruments Europe BV, Badhoevedorp, the Netherlands). Image capture and quantification was performed using the Lucia G morphometry software (Lucia G; Laboratory Imaging Ltd, Prague, Czech Republic). For Â 1000 images and for overview images at Â 25 magnification, we used a Leica DMLB light microscope with Leica N Plan objectives (Leica Microsystems, Wetzlar, Germany). The images were captured with an Olympus Colorview soft imaging system camera and the Olympus DP-Soft 5.0 Software (Olympus, Mü nster, Germany).
Evaluation of proliferative indices
In the short-time treatment group, proliferative indices (Ki-67-positive cells) were evaluated in non-infected regions, infected plaques and in areas immediately bordering plaques in Â 400 fields (Figure 1b) . To determine precise delineation of plaques and neighboring non-infected fields, we assessed the morphological characteristics of the cells in sections that were doublestained against HSV and Ki-67. For the GBMI xenograft injected with G207, five fields with plaques, five noninfected fields and six plaque-neighboring fields were analyzed. Again, five fields from a non-vector injected lesion served as controls. For the GBMII xenograft injected with G207, five fields with plaques, five noninfected fields and eight plaque-neighboring fields were analyzed; five fields from a non-vector injected lesion served as controls.
In the later effects study, we analyzed 10 Â 400 fields from each animal; in the vector group five fields with plaques and five fields outside plaques, whereas in the saline-injected control group, five fields from the tumor center and five from the tumor periphery were analyzed.
Evaluation of apoptotic counts
Apoptotic counts were analyzed in Â 400 fields after staining against activated caspase-3. Both positive cells (whole cytoplasms) and cell fragments were counted within infected plaques as well as in non-infected regions. For the GBMI lesion, four fields containing plaques were analyzed and compared with 10 fields in a non-infected tumor. For the GBMII lesion injected with G207, four tumor sections were stained. A total of 2-4 fields per section were analyzed for a total of 10 fields containing plaques and 16 non-infected fields. Ten fields from one immunostained section of a non-injected control lesion served as controls. For GBMIII lesions, we compared infected and non-infected foci from each of the five treatment group animals (5-10 infected and 5-10 non-infected fields from each lesion, for a total of 90 fields analyzed).
Evaluation of vessel density
To evaluate if local delivery of G207 had effects on the tumor vasculature, we used animals implanted with GBMIII spheroids and injected the established lesions with 6.8 Â 10 6 PFU G207 4 weeks post implantation. The animals were kept for 30 days post-injection before the brains were harvested and evaluated (long-term effects treatment group). We evaluated one von Willebrand factor-immunostained section per animal. Images were captured at Â 400 magnification. In the control group (n ¼ 5 animals), both central (5 pictures) and peripheral tumor regions (4-5 pictures) were taken from each of the animals for a total of 48 fields. From the G207-injected brains (n ¼ 5 animals), we captured 3-5 fields with plaques and 4-5 fields without plaques from each animal, for a total of 23 fields with plaques and 22 fields outside plaques. The infected regions were selected by observing cytolytic clearing and nuclear signs of infection and verified by correlating these fields to adjacent sections immunostained for HSV-1 antigens. When collecting data from microscopic fields with plaques, we only included images where the plaques occupied at least half of the visual field. The images were evaluated using the Lucia G morphometry software (Lucia G; Laboratory Imaging Ltd) and the number of vessels per field was counted. We applied the following criteria to score vessel density. Only positively stained structures were counted. We counted structures with clearly identifiable lumens or structures containing erythrocytes. Elongated structures with lengths that corresponded to several cells in length and structures with bends were counted. We did not count positive single cells. Structures containing erythrocytes with clear borders and observable positively stained rim at least on one side were counted to discern vessels from occasional free erythrocytes, which indicated small hemorrhages. Positively stained structures that evidently belonged to the same vessel were counted as one, whereas each degree of branching more than one bend was counted as one more vessel.
The data from different animals in one group were pooled, and thus the results are given as a medians and means for the control group, for plaques in the treatment group and for non-infected regions in the treatment group.
Evaluation of vessel area fractions
For the quantification of areas per microscopic field occupied by blood vessels, we used the same Â 400 images as used for vessel density counting. We chose 12 fields containing plaques and 12 fields containing non-infected regions in G207-injected tumors. Twelve fields from saline-injected animals served as controls. The images were opened in the Lucia G morphometry software. The investigators selected the vessels to be included following the same criteria as above. The vessel lumens were highlighted using the software tools and the selected areas were quantified. Results are given as percentages of the Â 400 field occupied by microvessels.
Statistical methods
Descriptive results are given as means, standard deviations (s.d.) and standard errors of the mean (s.e.m.).
For each staining, the histograms of positively stained cell numbers from each group (saline-injected lesions, plaque, plaque-border fields and non-infected areas in vector-injected lesions) were plotted to allow evaluation of the sample distribution. In all cases, the comparisons contained variables that did not follow normal sample distribution. Thus, two groups were compared using the Mann-Whitney U-test, where two-tailed exact significance values are reported. Several groups were compared with the Kruskal-Wallis test using Bonferroni's correction. When testing for proliferative indices, apoptotic indices, vessel densities and vessel area fractions in the later-effects study, mixed linear model analyses using compound symmetry covariance structure were applied. Residuals from the analyses were inspected for normal distribution, and log-transformed data were similarly analyzed. SPSS 15.0 was used for all analyses and a significance level of 0.05 was chosen.
